(NARI) – StreetInsider.com Reports
-
Inari Medical Inc. (NARI) PT Lowered to $62 at Baird
-
Inari Medical Inc. (NARI) PT Lowered to $47 at Truist Securities
-
Inari Medical (NARI) Appoints Tim Benner as Senior Vice President of U.S. Sales, Dr. Andrew Niekamp as Vice President of Medical Affairs
-
Inari Medical Inc. (NARI) PT Lowered to $52 at Truist Securities
-
Inari Medical (NARI) Reports Interim Two-Year Results from the ClotTriever CLOUT Registry
-
Inari Medical, Inc. (NARI) options active
-
Inari Medical Inc. (NARI) PT Lowered to $75 at Morgan Stanley
-
Piper Sandler Downgrades Inari Medical Inc. (NARI) to Neutral
-
Inari Medical Inc. (NARI) PT Lowered to $75 at Canaccord Genuity
-
Inari Medical Inc. (NARI) PT Lowered to $61 at Truist Securities
-
Inari Medical Inc. (NARI) PT Lowered to $74 at Baird
-
Inari Medical Inc. (NARI) PT Lowered to $86 at BTIG
-
Inari Medical, Inc. (NARI) Misses Q4 EPS by 9c, Beats on Revenue
-
Inari Medical Inc. (NARI) PT Lowered to $63 at Truist Securities
-
Needham & Company Starts Inari Medical Inc. (NARI) at Buy
-
Inari Medical (NARI) Reports Prelim FY23 Revenue of $493.5M, Issues 2024 Guidance
-
Healthcare a contrarian idea into 2024 - these stocks could see upside
-
Inari Medical Inc. (NARI) PT Raised to $70 at Truist Securities
-
Inari Medical Inc. (NARI) PT Raised to $79 at Canaccord Genuity
-
Inari Medical (NARI) Announces First Patient Enrollment in PEERLESS II Trial
-
Inari Medical Inc. (NARI) PT Lowered to $68 at Canaccord Genuity
-
Inari Medical Inc. (NARI) PT Raised to $65 at Truist Securities
-
Inari Medical Inc. (NARI) PT Lowered to $85 at Piper Sandler
-
Inari Medical, Inc. (NARI) Tops Q3 EPS by 4c
-
Inari Medical (NARI) to Acquire LimFlow
-
Inari Medical Inc. (NARI) PT Lowered to $65 at Baird
-
Inari Medical Inc. (NARI) PT Lowered to $60 at Truist Securities
-
Inari Medical, Inc. (NARI) Tops Q2 EPS by 17c
-
Nephron Starts Inari Medical Inc. (NARI) at Buy
-
Inari Medical Inc. (NARI) PT Lowered to $65 at Truist Securities
-
Baird Starts Inari Medical Inc. (NARI) at Outperform
-
Inari Medical Inc. (NARI) PT Lowered to $85 at BofA Securities
-
Inari Medical Inc. (NARI) PT Raised to $80 at Canaccord Genuity
-
Inari Medical, Inc. (NARI) Tops Q4 EPS by 6c
-
Inari Medical Inc. (NARI) PT Raised to $77 at Canaccord Genuity
-
Inari Medical Inc. (NARI) PT Lowered to $65 at Truist Securities
-
Inari Medical Inc. (NARI) PT Raised to $91 at Jefferies
-
Inari Medical (NARI) Reports Prelim Q4 Revenue of $107M-$108M
-
Inari Medical Inc. (NARI) PT Lowered to $83 at Morgan Stanley
-
Inari Medical Inc. (NARI) PT Lowered to $75 at Truist Securities
-
Inari Medical Inc. (NARI) PT Raised to $84 at Truist Securities
-
Inari Medical Inc. (NARI) PT Raised to $100 at BTIG
-
Inari Medical, Inc. (NARI) Tops Q3 EPS by 6c
-
Inari Medical Inc. (NARI) PT Lowered to $80 at Truist Securities
-
Inari Medical Inc. (NARI) PT Lowered to $97 at BTIG
-
Jefferies Starts Inari Medical Inc. (NARI) at Buy
-
Berenberg Starts Inari Medical Inc. (NARI) at Buy
-
UPDATE: Truist Starts Inari Medical Inc. (NARI) at Hold (correction)
-
Inari Medical, Inc. (NARI) Announces CEO Resignation, Appoints COO Drew Hykes as New CEO
-
UPDATE: Piper Sandler Starts Inari Medical Inc. (NARI) at Overweight
Back to NARI Stock Lookup